Evaluating the Cost-Effectiveness of Etranacogene Dezaparvovec Gene Therapy for Hemophilia B Treatment in the USA.
Saved in:
| Title: | Evaluating the Cost-Effectiveness of Etranacogene Dezaparvovec Gene Therapy for Hemophilia B Treatment in the USA. |
|---|---|
| Authors: | Sarker J; Department of Pharmacy Systems, Outcomes, and Policy, Retzky College of Pharmacy, University of Illinois Chicago, Chicago, IL, USA. jsarke3@uic.edu., Tice JA; Division of General Internal Medicine, University of California San Francisco, San Francisco, CA, USA., Rind DM; Institute for Clinical and Economic Review, Boston, MA, USA., Walton SM; Department of Pharmacy Systems, Outcomes, and Policy, Retzky College of Pharmacy, University of Illinois Chicago, Chicago, IL, USA. |
| Source: | Applied health economics and health policy [Appl Health Econ Health Policy] 2025 May; Vol. 23 (3), pp. 467-478. Date of Electronic Publication: 2024 Dec 02. |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Open Mind Journals Ltd Country of Publication: New Zealand NLM ID: 101150314 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1179-1896 (Electronic) Linking ISSN: 11755652 NLM ISO Abbreviation: Appl Health Econ Health Policy Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 1179-1896 |
|---|---|
| DOI: | 10.1007/s40258-024-00932-x |
